Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
There is no change in the price for Pacira Pharmaceuticals today.
Our community is currently high on Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 30 € shows a positive potential of 42.86% compared to the current price of 21.0 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.000% | -11.017% | -5.405% | -1.869% | -2.778% | -38.235% | -56.067% |
| Supernus Pharmaceuticals | 0.000% | 7.407% | -4.245% | 15.341% | -5.581% | 40.972% | 97.087% |
| Corcept Therapeutics Inc. | -1.560% | 1.786% | 20.373% | 56.341% | 41.708% | 241.197% | 432.418% |
| Collegium Pharmaceutical Inc | -0.850% | -24.026% | -24.026% | -23.529% | -43.478% | 8.333% | 49.045% |
Comments
Pacira BioSciences (PCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (PCRX) had its price target raised by Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat